Accepted Manuscripts
in Endocrine-Related CancerArticles are added to the current issue and list of accepted manuscripts on an ongoing basis, reflecting the journal's continuous publication.
Sign up using the buttons to receive email notifications of the latest research.
-
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancerArticle Number: ERC-23-0012
-
COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE studyArticle Number: ERC-22-0395
-
-
Germline pathogenic variants in patients with early onset neuroendocrine neoplasmsArticle Number: ERC-22-0258
-
-
Interventional versus surgical procedures in localized/nonmetastatic insulinoma (ablation versus surgery)Article Number: ERC-22-0362
-
Metabolomics in paraganglioma: applications and perspectives from genetics to therapyArticle Number: ERC-22-0376
-
Proteomic analysis of small intestinal neuroendocrine tumors and mesenteric fibrosisArticle Number: ERC-22-0237
-
Reactivated thyroid hormone receptor β attenuates ATC stem cell activityArticle Number: ERC-22-0306
-
Type 2 deiodinase is expressed in anaplastic thyroid carcinoma and its inhibition causes cell senescenceArticle Number: ERC-23-0016
-
Aggressive versus indolent insulinomas – new clinicopathological insightsArticle Number: ERC-22-0321
-
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspringArticle Number: ERC-22-0233
-
-
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic reviewArticle Number: ERC-22-0338
-
Progress and challenges in experimental models for pheochromocytoma and paragangliomaArticle Number: ERC-22-0405
-
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitorsArticle Number: ERC-22-0269
-